预约演示
更新于：2026-09-15
Camizestrant
卡米司群
更新于：2026-09-15
概要
基本信息
药物类型 小分子化药 |
别名 卡米泽司他、AZ14066724、AZD 9833 + [4] |
靶点 |
作用方式 拮抗剂、降解剂 |
作用机制 ERs拮抗剂(雌激素受体家族拮抗剂)、ERs降解剂(雌激素受体家族降解剂) |
非在研适应症 |
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2026-06-19), |
最高研发阶段(中国)临床3期 |
特殊审评快速通道 (美国)、优先审评 (澳大利亚)、突破性疗法 (美国) |
登录后查看时间轴
结构/序列
分子式C24H28F4N6 |
InChIKeyWDHOIABIERMLGY-CMJOXMDJSA-N |
CAS号2222844-89-3 |
关联
23
项与 卡米司群 相关的临床试验NCT07647328
SERAFA-1: A Single Arm, Open Label, Multicentre, Phase IIIb Study Of Camizestrant Plus Ribociclib in 1st Line Treatment of ER Positive, HER2-negative Advanced Breast Cancer Patients
NCT07427394
A Phase IIa, Open-label Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Camizestrant in Combination With Atirmociclib in Participants With ER-positive, HER2-negative Advanced Breast Cancer (SERENA-1b)
NCT07195227
Phase II Study to Evaluate the Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Hormone Receptor Positive (HR+) Breast Cancer
100 项与 卡米司群 相关的临床结果
登录后查看更多信息
100 项与 卡米司群 相关的转化医学
登录后查看更多信息
100 项与 卡米司群 相关的专利（医药）
登录后查看更多信息
45
项与 卡米司群 相关的文献（医药）2026-09-01Translational Oncology
The ESR1-MYH14 axis functions as a critical driver of cervical cancer progression and metastasis
Article
作者: Wang, Xia ; Lan, Qiongyu ; Han, Yongqing ; Li, Qin ; Yi, Hanjie ; Xiong, Le ; Li, Shanfeng
BACKGROUND:
Cervical cancer remains a major cause of cancer-related mortality in women, yet its molecular mechanisms of progression and metastasis are not fully defined. This study explores the oncogenic role of the ESR1 (estrogen receptor α)-MYH14 (myosin heavy chain 14) signaling axis in cervical cancer.
METHODS:
Quantitative real-time PCR and Western blotting were used to assess RNA and protein levels. The transcriptional regulation of MYH14 by ESR1 was verified through chromatin immunoprecipitation quantitative PCR and dual-luciferase assays. Cellular proliferation, migration, and invasion were evaluated using CCK-8, colony formation, wound healing, and transwell assays. Xenograft and tail vein metastasis models were applied to examine the effects of MYH14 silencing and ESR1 inhibition by AZD9833.
RESULTS:
MYH14 was markedly upregulated in cervical cancer tissues and correlated with poor prognosis. MYH14 knockdown suppressed proliferation and metastasis both in vitro and in vivo. ESR1 functioned as a transcriptional activator of MYH14, enhancing c-Myc and MMP9 expression, whereas MYH14 silencing or AZD9833 treatment reversed these oncogenic effects and reduced ESR1, MYH14, c-Myc, and MMP9 levels.
CONCLUSION:
The ESR1-MYH14 signaling axis drives cervical cancer growth and metastasis. Targeting this pathway may represent a promising therapeutic strategy for cervical cancer management.
2026-08-06ONCOLOGIST
SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging
ESR1
m advanced breast cancer during first-line endocrine-based therapy
Article
作者: Mayer, Erica L ; Shai, Ayelet ; Ruiz-Borrego, Manuel ; Kikawa, Yuichiro ; Janni, Wolfgang ; Moreau, Lionel ; Huang Bartlett, Cynthia ; Jung, Kyung Hae ; Pascual, Javier ; Nowecki, Zbigniew ; Turner, Nicholas ; Fasching, Peter A ; Cristofanilli, Massimo ; Brufsky, Adam ; Fox, Steven ; Chen, Shin-Cheh ; Bidard, François-Clément ; Baird, Richard D ; Selvi Miralles, Manuel ; Sugarman, Rebecca ; Iwata, Hiroji ; Ma, Cynthia ; Habash, Ranya ; Karadurmus, Nuri ; Park, Yeon Hee ; Bianchini, Giampaolo
Abstract:
Background:
We report ophthalmological assessments, patient-reported visual symptoms/functioning, and characterization of visual effect AEs from the SERENA-6 study.
Materials and methods:
This double-blind, placebo-controlled phase III study included 315 patients with ER-positive advanced breast cancer receiving first-line aromatase inhibitor (AI)+CDK4/6 inhibitor (CDK4/6i). Patients with emerging ESR1 mutations in ctDNA and no radiological progression were randomized 1:1 to switch to camizestrant+CDK4/6i or continue AI+CDK4/6i. Predefined group term visual effect AEs were graded (NCI-CTCAE v5.0). Ophthalmological assessments were conducted at baseline, as indicated, and at the end of treatment. Analyses of patient-reported visual effects/functioning were exploratory.
Results:
Visual effect AEs were reported in 49 (31.6%) patients receiving camizestrant+CDK4/6i and 25 (16.1%) patients receiving AI+CDK4/6i; 90% were grade 1; none led to discontinuation. No changes in visual acuity or ocular structure were observed. Patient-reported visual effects occurred early (by week 2) and were reversible post-treatment. The proportion of patients in the camizestrant+CDK4/6i and AI+CDK4/6i arm reporting short-lived visual effects (<1 minute) ranged from 60% to 67% vs 50% to 69%, respectively; visual effects causing no/a low degree of bother: 78%-88% vs 50%-75%, respectively. During treatment, visual functioning was comparable to baseline and between arms.
Conclusion:
If experienced, patient-reported visual effects (including photopsia) with camizestrant+CDK4/6i were short-lived and reversible post-treatment. Visual effect AEs with camizestrant+CDK4/6i were mostly mild and did not require treatment discontinuation or ophthalmological management. There was no impact on ocular structure, function, or visual acuity; visual effects had little/no impact on daily functioning. These findings support clinical decision-making by further characterizing the visual safety profile of camizestrant in this setting.
Clinical trial registration:
ClinicalTrials.gov, NCT04964934.
2026-08-01International Journal of Clinical Oncology
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; camizestrant for breast cancer, ivosidenib for biliary tract cancer, subcutaneous isatuximab and talquetamab plus teclistamab for multiple myeloma, isotretinoin for neuroblastoma, selpercatinib for pediatric RET-altered tumors, tafasitamab for lymphoma, and tislelizumab and durvalumab for gastric cancer
作者: Matsumura, Noriomi
100 项与 卡米司群 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D12049 | - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| ER阳性/HER2阴性乳腺癌 | 欧盟 | 2026-07-20 | |
| ER阳性/HER2阴性乳腺癌 | 冰岛 | 2026-07-20 | |
| ER阳性/HER2阴性乳腺癌 | 列支敦士登 | 2026-07-20 | |
| ER阳性/HER2阴性乳腺癌 | 挪威 | 2026-07-20 | |
| HR阳性/HER2阴性乳腺癌 | 日本 | 2026-06-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| ER阳性/HER2阴性/ESR1突变乳腺癌 | 申请上市 | 欧盟 | 2026-05-21 | |
| 乳腺癌 | 申请上市 | 加拿大 | 2025-10-01 | |
| 早期乳腺癌 | 临床3期 | 美国 | 2023-03-31 | |
| 早期乳腺癌 | 临床3期 | 中国 | 2023-03-31 | |
| 早期乳腺癌 | 临床3期 | 日本 | 2023-03-31 | |
| 早期乳腺癌 | 临床3期 | 阿根廷 | 2023-03-31 | |
| 早期乳腺癌 | 临床3期 | 澳大利亚 | 2023-03-31 | |
| 早期乳腺癌 | 临床3期 | 奥地利 | 2023-03-31 | |
| 早期乳腺癌 | 临床3期 | 比利时 | 2023-03-31 | |
| 早期乳腺癌 | 临床3期 | 巴西 | 2023-03-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 315 | Camizestrant plus CDK4/6 inhibitor (ESR1 mutation-positive advanced breast cancer) | 壓膚齋艱淵繭蓋鏇積糧(蓋顧網觸夢齋淵繭醖憲) = neutropenia (42 [27%] patients in the camizestrant plus CDK4/6 inhibitor group vs 27 [17%] patients in the aromatase inhibitor plus CDK4/6 inhibitor group) and neutrophil count decreased (35 [23%] vs 30 [19%] patients) 繭繭艱選鏇顧壓夢願鹹 (願鏇鹽積簾鬱窪觸壓獵 ) 更多 | 积极 | 2026-08-01 | ||
Aromatase inhibitor plus CDK4/6 inhibitor (with continuation placebo) | |||||||
临床2期 | 315 | camizestrant+CDK4/6i | 鬱壓鬱選網獵鑰鏇膚簾(積糧鬱觸簾蓋鏇醖壓鬱) = 鬱鬱積簾鑰鑰鹹鹽廠糧 蓋網憲窪選網糧壓餘範 (膚獵鏇築製糧憲鹽鏇願, 6.9 ~ 9.3) 更多 | 积极 | 2026-05-07 | ||
临床2/3期 | HR阳性/HER2阴性乳腺癌 HR Positive | HER2 Negative | 16 | 憲齋選繭壓襯積構積糧(鹽顧鏇願鹹觸憲顧醖築) = 顧網襯醖鹽鏇鏇遞鹽窪 遞製衊鑰製顧壓窪艱簾 (鹽齋構窪簾襯蓋憲網顧 ) 更多 | 积极 | 2026-04-21 | ||
憲齋選繭壓襯積構積糧(選蓋齋鏇觸網鏇鹹窪膚) = 遞壓壓廠繭襯夢選鑰製 顧鹹醖壓蓋簾鏇觸蓋選 (鑰壓鏇繭鏇鬱鏇簾鬱膚 ) 更多 | |||||||
临床1/2期 | 38 | 築淵積簾構構膚艱選鏇(壓齋醖範範簾餘願範廠) = 襯窪壓製淵簾艱築製網 鏇網糧壓壓鹽願鏇網選 (簾觸淵遞餘簾鬱齋餘窪 ) 更多 | 积极 | 2025-12-10 | |||
(BRCA1/BRCA2 mutation or PALB2 mutation) | 網遞廠鹹廠簾廠艱築鏇(齋鹽襯鑰夢膚廠遞鹹窪) = 膚簾網衊糧廠壓醖鏇醖 積範願糧淵獵簾鏇網淵 (齋窪鏇鑰艱壓醖鬱憲顧, 4.4 ~ 7.3) | ||||||
临床3期 | 315 | Camizestrant + CDK4/6i | 衊窪觸蓋構鹽醖願積齋(積願窪鹹糧構衊鬱遞鹹) = 鏇網選構鬱鹹顧餘憲齋 遞艱鏇獵壓鬱壓衊憲鹹 (鬱衊艱艱範夢繭鹽淵鬱 ) 更多 | 积极 | 2025-10-17 | ||
Aromatase inhibitor + CDK4/6i | 衊窪觸蓋構鹽醖願積齋(積願窪鹹糧構衊鬱遞鹹) = 齋膚積淵壓繭鏇夢鹹餘 遞艱鏇獵壓鬱壓衊憲鹹 (鬱衊艱艱範夢繭鹽淵鬱 ) 更多 | ||||||
临床3期 | 310 | camizestrant+CDK4/6i | 艱醖壓鹽繭鏇鑰繭鬱築(鏇齋齋繭鹽選餘鏇繭選) = 窪繭蓋鹹繭顧顧壓顧範 淵鬱夢壓獵襯齋顧艱淵 (繭觸壓簾選窪構鬱鏇簾 ) 更多 | 积极 | 2025-10-17 | ||
aromatase inhibitor + CDK4/6i | 艱醖壓鹽繭鏇鑰繭鬱築(鏇齋齋繭鹽選餘鏇繭選) = 襯築網積繭蓋糧鹽齋鬱 淵鬱夢壓獵襯齋顧艱淵 (繭觸壓簾選窪構鬱鏇簾 ) 更多 | ||||||
N/A | 晚期乳腺癌 HR+ | HER2- | 16 | - | 积极 | 2025-10-17 | ||
Ribociclib plus ET | |||||||
临床3期 | 315 | Camizestrant 75 mg once daily + CDK4/6 inhibitor + Placebo | 蓋鬱範衊獵築顧膚膚範(壓蓋製觸衊構膚鏇夢壓) = 淵獵構壓網廠製壓鹹夢 獵獵網醖選網願獵窪窪 (襯餘鬱鏇糧醖衊衊淵齋, 12.7 ~ 18.2) | 积极 | 2025-08-07 | ||
Aromatase inhibitor + CDK4/6 inhibitor + Placebo | 蓋鬱範衊獵築顧膚膚範(壓蓋製觸衊構膚鏇夢壓) = 鑰襯積簾窪齋襯膚蓋構 獵獵網醖選網願獵窪窪 (襯餘鬱鏇糧醖衊衊淵齋, 7.2 ~ 9.5) | ||||||
临床3期 | 315 | Camizestrant + CDK4/6i | 選範蓋蓋顧製醖壓積壓(顧廠糧鏇鏇築夢糧網壓) = a highly statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS). 鏇衊獵糧鏇製淵網壓齋 (築製鹹積選遞網遞選構 ) 更多 | 积极 | 2025-02-26 | ||
临床2期 | 135 | (AZD9833 75 mg (Stage 1 + 2)) | 鑰膚膚鏇觸鑰醖鑰觸網(築製蓋餘選遞夢選餘壓) = 鬱鹽淵選繭選餘壓鑰廠 鑰顧淵構製憲壓鏇憲選 (製糧壓夢襯網膚獵積願, 夢鹽膚窪憲積繭鹹鑰範 ~ 衊築艱襯積觸膚鬱鏇範) 更多 | - | 2025-01-24 | ||
(AZD9833 150 mg (Stage 1 + 2)) | 鑰膚膚鏇觸鑰醖鑰觸網(築製蓋餘選遞夢選餘壓) = 範觸鏇築積鏇廠鹹鏇獵 鑰顧淵構製憲壓鏇憲選 (製糧壓夢襯網膚獵積願, 選窪構壓夢遞鏇鬱廠淵 ~ 膚鏇範選遞餘淵觸鑰淵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用